Neurofibromatosis and Schwannoma CasesNeuroblastoma Research and TreatmentsMeningioma and schwannoma managementSarcoma Diagnosis and TreatmentMelanoma and MAPK Pathways
Publications
571
Citations
2,710
Est. group size
~2
Recurring co-author estimate
Active years
28
Publishing since 1999
Publication cadence
Publications per year over the last 10 years — averaging 98.2/year recently
Recent publications
- Abstract 6017: BET inhibition potentiates salvage chemotherapy response through TXNIP upregulation in osteosarcoma
Cancer Research · 2026
- Proteomic approaches for interrogating kinase signaling networks
Journal of Investigative Dermatology · 2026
- Supplementary Figure S1 from Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group
2026
- Supplementary Table 8 from Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma
2026
- Supp fig 3 from PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid Leukemia
2026
- Supplementary Table 8 from Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma
2026
- Supplementary Table 8 from Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma
2026
- Supplementary Figure S6 from Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group
2026
- Supplementary Table 9 from Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma
2026
- Supplementary Table S5 from Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group
2026
- Supplementary Table 9 from Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma
2026
- Supplementary Data from PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid Leukemia
2026
- Supplementary Table 8 from Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma
2026
- Supplementary Table 9 from Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma
2026
- Supplementary Data from PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid Leukemia
2026
Publishes in
- Cancer Research×17
- UNC Libraries×14
- Neuro-Oncology×13
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Clinical Cancer Research×4
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile